Search

everythinglearnresearchcommunity

for

Search:↓

A specific DNA sequence caused hair loss in male mice by activating immune cells and increasing a certain immune signal.

Hormone therapy is essential for transgender individuals but requires careful management due to possible metabolic effects.

Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.

Hormone treatment for transgender patients may not need to be stopped before surgery, but more research is needed, especially on estrogen.

New male hormonal contraceptives show promise but need more research on long-term effects and funding for larger trials.

Adiantum capillus-veneris Linn reduced hair loss and improved hair growth in mice with testosterone-induced alopecia.

Hormone therapy is safe and effective for transgender adults, but requires regular monitoring and mental health support.

The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.

The finasteride patch effectively treats hair loss by enhancing skin absorption.

Cyproterone acetate is a safe treatment that causes mild feminizing effects and is more effective with added estrogens.

Estrogen alone may effectively suppress testosterone in some transfeminine individuals.

Exogenous testosterone use may be linked to developing hidradenitis suppurativa.

A man with severe hair loss regrew hair after hormone treatment.

Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

The report recommends personalized treatment for women's sexual dysfunctions and more research on effective therapies.

New treatments for male hypogonadism are effective and should be personalized.

Androgens play a role in female sexual function, and testosterone therapy can help women with low sexual desire, but more research is needed on treatments and long-term safety.

The conclusion is that published guidelines are improving transgender medical care, but more research and education in transgender medicine are needed.

The review recommends hormone replacement therapy for women with premature ovarian insufficiency to manage symptoms and protect health, with specific approaches for different groups.

Androgen conjugates might be better indicators of skin sensitivity to hormones in women with excessive hair growth.

Some medications can cause acne, and stopping these drugs is the main treatment.

Testosterone replacement may improve sexual desire and bone health in women with low androgen levels, but more research is needed on its long-term safety.

Testosterone therapy is generally safe for transmen, improves sexual function, and has manageable health risks with proper monitoring.

Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.

Testosterone therapy seems safe and effective for transgender men with proper care, but more long-term research is needed.

Testosterone therapy can improve sexual desire and function in postmenopausal women but should be used cautiously and not based solely on testosterone levels.

New treatments for low male hormones improved sexual function and mood but had unclear risks, especially for older men.